Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Belgium: Wellvone; France: Wellvone; Germany: Wellvone; Greece: Wellvone; Italy: Wellvone; Netherlands: Wellvone; Poland: Mepron; Portugal: Wellvone; Spain: Wellvone; Sweden: Wellvone; UK: Wellvone.

North America

Canada: Mepron; USA: Mepron.

Drug combinations

Atovaquone and Proguanil


Atovaquone: C~22~H~19~ClO~3~. Mw: 366.84. (1) 1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans-; (2) 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone. CAS-95233-18-4 (1993).

Pharmacologic Category

Miscellanous Antiprotozoals. (ATC-Code: P01AX06).

Mechanism of action

May inhibit electron transport in mitochondria inhibiting metabolic enzymes.

Therapeutic use

Treatment and profilaxis of Pneumocystis carinii pneumonia in intolerance to co-trimoxazole. Treatment of Toxoplasma gondii encephalitis. Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.

Pregnancy and lactiation implications

Use during pregnancy only if potential benefit outweighs possible risk to the fetus. Caution during lactation.

Unlabeled use


Life-threatening allergic reaction to the drug or formulation.

Warnings and precautions

Absorption may be decreased in diarrhea or vomiting. Use with caution in severe hepatic impairment or in elderly patients (potentially impaired renal, hepatic, and cardiac function).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart